Merck KGaA’s life science unit is still feeling the Covid demand decline
A single Covid project that’s not been renewed made an earnings dent in Merck KGaA’s manufacturing arm in the third quarter, but the company is looking to reassure investors that orders are picking up...
View ArticleBeiGene rebrands as BeOne Medicines, dropping name's link to China
The global pharma company whose name rhymes with the capital of China wants people to know that it is not in fact a Chinese company, and is proposing a name change to more emphatically make ...
View ArticleAs bluebird projects more commercial demand, the biotech continues to seek cash
Bluebird bio reported that 17 people with sickle cell disease have started the process of receiving its gene therapy Lyfgenia. Bluebird said in its third-quarter earnings Thursday that it recognized...
View ArticleZai Lab aims to raise $200M; Kronos Bio to seek ‘strategic’ options
Plus, news about Allogene, Telix, Cullgen, Pulmatrix, Gilead, Innocoll, Durect and Sensei: Zai Lab’s $200M offering: The Shanghai-based drugmaker is selling shares the same week as announcing revenue...
View ArticleNovo Nordisk to phase out its production of human insulin pens globally
Novo Nordisk said Thursday that it plans to eventually halt all of its human insulin pen production globally, confirming an Endpoints News report from September. "We do continue to make human insulin ...
View ArticleNew Zealand clears first clinical trial of epigenetic editing for hepatitis B
Tune Therapeutics announced Thursday that New Zealand health authorities are allowing the company to study its experimental epigenetic editing therapy for chronic hepatitis B in humans. It’s the first...
View ArticleLonza expands bioconjugates factory; WuXi Bio adds capacity in Germany
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lonza said it is expanding a facility in Visp, Switzerland, to house ...
View ArticleEuropean Commission seeks biopharma feedback on Novo-Catalent deal — report
The European Commission is asking biopharma and manufacturing companies about their reaction to Novo Holdings’ proposed acquisition of Catalent, according to Reuters. While the EC declined to comment...
View ArticleLouisiana's Bill Cassidy named next chair of Senate health committee
Sen. Bill Cassidy (R-LA) will take over the Senate Health, Education, Labor, and Pensions Committee when the GOP gets control of the chamber in the next Congress, offering a change of pace on some...
View ArticleArc Institute debuts AI model Evo, makes new CRISPR systems
Less than a decade ago, a slew of startups like Metagenomi and Mammoth Biosciences raised huge sums of money to advance CRISPR gene editing systems found in nature. ...
View ArticleEuropean drug regulator reverses opinion on Eisai and Biogen's Alzheimer's drug
The European Medicines Agency has flipped its stance on Eisai and Biogen’s Alzheimer’s treatment Leqembi, recommending authorization in a narrower population than it previously considered. The agency's...
View ArticleGilead to close Philadelphia and Seattle offices, make job cuts
More layoffs are hitting Gilead’s cell therapy wing, including the closure of a Philadelphia office. The company confirmed to Endpoints News that the office acquired in its Tmunity purchase is being...
View ArticleFDA says Merz's social media promotion with Nate Berkus is 'misleading'
Merz Therapeutics landed in hot water last month when the FDA said a social media promotion for its Botox rival Xeomin was “false or misleading." Now the company is trying to smooth things over. ...
View ArticlePresident-elect Trump selects Robert F. Kennedy Jr. to lead HHS
President-elect Donald Trump has picked Robert F. Kennedy Jr. to be his next HHS secretary, likely giving the government's most powerful healthcare post to a vaccine skeptic whose controversial views...
View ArticleAdaptimmune to 'redefine' itself as a sarcoma biotech, cuts a third of staffers
Adaptimmune is slashing its headcount as part of a broader company restructuring aimed at saving $300 million over the next few years through 2028. The company said it will lay off 33% of its employees...
View ArticleALX Oncology hires Genentech, Mirati vet as CMO; After Carmot, Heather Turner...
ALX Oncology has found a new chief medical officer, tapping Alan Sandler for the role. Sandler comes to ALX from Mirati, where he was CMO before its acquisition by Bristol Myers Squibb earlier this...
View ArticleEvotec gains on Halozyme's takeover proposal
Halozyme said Thursday post-market that it wants to buy Evotec for €11 per share in cash, giving the struggling drug discoverer and manufacturer an equity value of €2 billion. Evotec's shares ...
View ArticleVitalli ends work on Daewoong asset; Alector’s $50M loan
Plus, news about Bavarian Nordic, Nuvectis Pharma, Flashpoint Therapeutics, Sparian Biosciences and TFF Pharmaceuticals: Vitalli Bio axes Daewoong asset: Vitalli, founded by Joe Jimenez’s Aditum Bio,...
View ArticleBoston Pharmaceuticals' Phase 2 MASH trial hits efficacy endpoints
Boston Pharmaceuticals succeeded on two closely watched efficacy endpoints for its Phase 2 MASH study, putting the company in contention with other biotechs seeking to treat the liver disease. The...
View Article